V. Son

Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.

C. Wykoff, F. Asmus, N. Waheed, 2019, Ophthalmology.

A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.

A. Catapano, M. Harada‐Shiba, Shazia Ali, 2020, Atherosclerosis.

Evinacumab in Patients with Refractory Hypercholesterolemia.

D. Gaudet, R. Hamlin, R. Rosenson, 2020, The New England journal of medicine.

A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia

D. Gaudet, D. Rader, C. Ballantyne, 2021, Atherosclerosis.

Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program

D. Wolf, B. Feagan, F. Rieder, 2022, Contemporary clinical trials.